1 / 19

AV THERAPEUTICS

A New York Based Biotechnology Company. AV THERAPEUTICS. Investor presentation. “Better Treatment of Cancer through Innovation ”. Except for historical information, the statements made in this presentation are forward looking statements involving significant risks and uncertainties.

alda
Download Presentation

AV THERAPEUTICS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A New York Based Biotechnology Company AV THERAPEUTICS Investor presentation “Better Treatment of Cancer through Innovation” Except for historical information, the statements made in this presentation are forward looking statements involving significant risks and uncertainties. JAN 2014

  2. Forward-Looking DisclosureAll statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for AV Therapeutic(The Company) products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited, to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights and other risks discussed in the Company’s registration statement on Form S-1 and other reports filed with the Securities and Exchange Commission which is available for review at www.sec.gov. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the Company's business. The Company disclaims any intent or obligation to update these forward-looking statements. .

  3. AV Therapeutics Stock Basics Data as of January 9, 2014 .

  4. Company Overview • Developing cancer therapeutics & immunotherapeutic vaccines that can be used alone or in combination with prevalent treatment modalities such as chemotherapy and radiation to treat active disease and to prevent metastases and recurrence. • Based on the ability of certain proprietary reagents to re-educate or reprogram an immune system to target previously unidentified micro-metastases. • Clinically developing both approaches for metastatic and early-stage prostate cancer. .

  5. AV Therapeutics: Developing Safer and More Effective Chemotherapeutic Agents .

  6. Management Team .

  7. The Problem - Prostate Cancer Effective drug based therapy and immunotherapyis an unmet clinical need in prostate cancer .

  8. Loss of Androgen Receptor Early Step in Prostate Tumor Progression Hormone Dependent Hormone Independent Loss of Androgen Receptor Upregulation of ER-b Upregulation of CDC25 group .

  9. The Solution: Capridine-β (C-1748) • Capridine is a patented chemotherapy drug • National Cancer Institute Tested Capridine for Prostate Cancer and other Cancers • Research funded by Dept. of Defense and National Institute of Health • Capridine and 200 of its derivatives are patented for use as anti-cancer agents • Limited Side Effects • Low Bone Toxicity .

  10. 2 1 Capridine-b Kills Prostate Cancer Preferentially Prostate cancer cell with Capridine-b Bone marrow cells with Capridine-b Prostate cancer cells are ten to 100 fold more sensitive to Capridine-b than bone marrow cells Data on file AV Therapeutics, Inc. .

  11. Capridine-β is a Potent Anticancer Drugin Several Cancers * *Mitoxantrane Data on file AV Therapeutics, Inc. .

  12. Salient Features of Capridine-β Data on file AV Therapeutics, Inc. .

  13. 13 .

  14. Development Plan for Capridine b – Next Steps • Limited rodent and dog toxicology with formulated product • Drug manufacture and formulation under GMP conditions • IND application • Phase I/II clinical trials • Stability testing of the formulated product • Pharmacokinetics and pharmacodynamics .

  15. Vaccine Response to Capridine .

  16. Scientific Advisory Board • Joseph Bertino, MD, Associate Director and Chief Scientific Officer, The Cancer Institute of New Jersey and past President of the American Association for Cancer Research and The American Association of Clinical Oncologists, organizations of over 50,000 researchers, worldwide. He is the founding Editor of the Journal of Clinical Oncology. • Charles Cantor, PhD, is Director of the Center for Advanced Biotechnology at Boston University and Chief Scientific Officer at Sequenom, Inc. in La Jolla (a publicly traded company). He has published more than 400 articles, and has been awarded more than sixty (60) patents. He is most known for his authoring of the book, Genomics: The Science and Technology Behind the Human Genome Project. • Roy G. Smith, PhD, is the Director of then Huffington Center on Aging, Professor in the Department of Molecular and Cellular Biology, and Professor in the Department of Medicine at Baylor College of Medicine. He was previously Vice President of Basic Research at Merck and was responsible for identifying new drug targets for metabolic diseases • Pramod Srivastava, PhD, is a Professor of immunology at the University of Connecticut, where he holds an Endowed Chair in Cancer Immunology and is the Director of the Cancer Center and the Scientific Founder of Antigenics. He is among the founding members of the Academy of Cancer Immunology. .

  17. Clinical Research Partner The Prostate Cancer Clinical Trials Consortium Howard Scher MD, Head of Clinical Consortium Confidential - not for distribution

  18. Investment Highlights • Outstanding physicians and world-renown clinical researchers • Developed Capridine, a patented drug having specific activity against prostate cancer • Capridine addresses a $2 billion market for treatment of prostate cancer • U.S. patent on combination of capridines with other agents • National Cancer Institute tested prostate cancer specific drug • Over $6 million dollars invested in development (pre-AVT) .

  19. Summary • Preclinical studies complete for Capridine. • Unique properties include no blood toxicity and wide therapeutic dose range with specificity towards prostate cancer • Ready to commence phase I and II human trials • World-Class, internationally recognized, scientists and clinicians (PhD’s and MDs) from A+ institutions • World class medical research collaborators and Scientific Advisory Board • All IP is patent protected .

More Related